Precision Gene Editing Applied to Small Molecule Drug Discovery

Light Horse Therapeutics is at the forefront of precision gene editing, specifically applied to small molecule drug discovery. The company has developed an advanced platform that identifies cryptic, chemically accessible functional domains within protein targets that are crucial to disease biology. This innovative approach aims to address the underlying causes of serious and life-threatening diseases, with an initial focus on challenging oncology targets. The technology not only enhances the understanding of these targets but also opens avenues for potential applications in other therapeutic areas in the future.

The company’s proprietary platform is built on a function-first discovery model, which allows for the identification of hidden functional sites on high-value protein targets. This method is designed to interrogate proteins in their native environments, thereby improving the accuracy and efficacy of drug discovery. Light Horse Therapeutics has garnered significant financial backing, including a $62 million Series A financing round, and has entered into strategic collaborations with major pharmaceutical companies like Novartis. The leadership team comprises experienced scientists and executives with a strong track record in biopharmaceutical development, further solidifying the company’s position in transforming drug discovery and advancing healthcare solutions.

United States

Light Horse is leading the way in precision genome editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases.  Its advanced platform identifies cryptic chemically accessible functional domains within targets that play critical roles in disease biology. The high-throughput discovery platform systematically interrogates complex signaling pathways to uncover unique sites of vulnerability. Light Horse interrogates these targets in their native, cellular context to best ensure that discoveries in the lab translate into the clinic. 

Light Horse Therapeutics

Company Details